The MOTS-c peptide, fully explained
The MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide encoded inside mitochondrial DNA. It activates AMPK — the cell's master energy sensor — and is studied for metabolism, insulin sensitivity, exercise capacity, and healthy aging. This page is the complete plain-English guide: what MOTS-c is, what it does, dosing context, safety, and the underlying research.
What is the MOTS-c peptide?
The MOTS-c peptide (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a small signaling peptide just 16 amino acids long. Unlike most peptide hormones, which are encoded in nuclear DNA, MOTS-c is encoded inside mitochondrial DNA — making it part of a unique family called mitochondrial-derived peptides (MDPs). It was discovered in 2015 by Changhan Lee and colleagues at USC.
MOTS-c is released into the bloodstream and acts on skeletal muscle, adipose tissue, liver, and bone. Its sequence is MRWQEMGYIFYPRKLR and its UniProt ID is A0A0C5B5G6.
How the MOTS-c peptide works
MOTS-c primarily activates AMP-activated protein kinase (AMPK), the enzyme cells use to sense low energy. Once AMPK is on, it triggers GLUT4-mediated glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis — the same downstream effects you get from exercise and from drugs like metformin. That's why papers often describe MOTS-c as an exercise-mimetic peptide.
MOTS-c peptide benefits
Across preclinical and early clinical research, MOTS-c has been studied for:
- Metabolic health — improved insulin sensitivity, reduced fasting glucose, prevention of diet-induced obesity in mice.
- Exercise capacity — restored running endurance in aged mice, increased mitochondrial density in muscle.
- Healthy aging — circulating MOTS-c declines with age and is lower in people with type 2 diabetes; supplementation reverses several markers of metabolic aging in animals.
- Bone & muscle — protection against age-related sarcopenia and post-menopausal bone loss in models.
- Cardiometabolic markers — improvements in lipid profile, hepatic steatosis (fatty liver), and inflammatory markers.
For deeper coverage with effect sizes and citations, see the MOTS-c benefits page.
MOTS-c peptide dosing
There is no validated human dose for MOTS-c. Animal studies cluster around 0.1–15 mg/kg via intraperitoneal injection. Anecdotal community protocols sit around 5–10 mg per week subcutaneous, often split into smaller injections. None of this is medical guidance — see the full MOTS-c safety and dosing page for context, contraindications, and the data gaps.
MOTS-c side effects & safety
Reported side effects are rare and mostly limited to injection-site reactions in early human work. The biggest concern is the absence of long-term human safety data and the theoretical risk of additive blood-glucose lowering when stacked with insulin, metformin, or GLP-1 agonists. MOTS-c is not approved by the FDA, EMA, or MHRA — it is sold strictly as a research chemical.
MOTS-c peptide research
The foundational studies span 2015 to today: Lee et al. discovered MOTS-c in Cell Metabolism (2015); Reynolds et al. showed it reverses age-dependent physical decline in Nature Communications (2021); Kim et al. characterized circulating MDPs and aging in Aging (2018). The MOTS-c research library tracks new studies as they publish.
MOTS-c vs other peptides
MOTS-c is often compared to GLP-1 agonists (semaglutide, tirzepatide), but they're fundamentally different: GLP-1s suppress appetite and slow gastric emptying; MOTS-c signals cellular energy status and improves insulin handling at the muscle level. It's closer in spirit to humanin — another mitochondrial-derived peptide — and to AMPK-activating compounds like metformin, but with a peptide signaling mechanism rather than a small-molecule one.
Where to find research-grade MOTS-c
MOTS-c is sold strictly as a research chemical — not for human consumption. The vendors below publish independent third-party Certificates of Analysis (COAs) and HPLC purity data for each batch, which is the bar we use before listing anyone. Some links are affiliate links; they never affect price or what we recommend.
Limitless Life Nootropics
Long-running US research-peptide vendor. Publishes third-party HPLC purity and identity reports for every batch of MOTS-c.
Pure Rawz
Wide research catalogue including MOTS-c. Independent purity testing posted per batch with consistent ≥98% purity.
Peptide Sciences
One of the largest research-peptide catalogues. Provides COAs on request and ships internationally.
Disclosure: outbound vendor links may be affiliate links. We only list vendors that publish third-party COAs and meet the criteria on our resources page. Editorial picks are never paid.
Get the MOTS-c research digest
One short email a month with new studies, takeaways, and protocols. No spam.
Frequently asked questions
What is the MOTS-c peptide?+
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the 12S rRNA region of mitochondrial DNA. It acts as a signaling molecule that activates AMPK, the cell's master energy sensor, regulating glucose metabolism, insulin sensitivity, and exercise capacity.
What does the MOTS-c peptide do?+
In studies, the MOTS-c peptide improves insulin sensitivity, increases glucose uptake in muscle, boosts fatty-acid oxidation, supports mitochondrial biogenesis, and restores exercise capacity in aged animals. It's frequently described as an 'exercise-mimetic' peptide.
What are the benefits of MOTS-c peptide?+
Reported benefits in preclinical and early human research include better metabolic health, improved insulin sensitivity, prevention of diet-induced obesity, increased endurance, protection against bone and muscle loss, and possible longevity effects tied to declining MOTS-c levels with age.
Is the MOTS-c peptide FDA approved?+
No. The MOTS-c peptide is not approved by the FDA, EMA, or MHRA for any indication. It is sold only as a research chemical. Any use outside a clinical trial is unregulated.
What is a typical MOTS-c peptide dose?+
There is no validated human dose. Animal studies use roughly 0.1–15 mg/kg. Anecdotal protocols in research communities range from about 5–10 mg per week, often split into smaller subcutaneous injections — but this is not medical guidance.
Are there MOTS-c peptide side effects?+
Reported side effects in human research are rare and mostly limited to injection-site reactions. Long-term safety data in humans is essentially absent, and interactions with diabetes medications (insulin, metformin, GLP-1 agonists) are theoretically possible because MOTS-c lowers blood glucose.
Where is MOTS-c peptide made in the body?+
MOTS-c is encoded inside mitochondrial DNA — specifically the 12S rRNA gene — and translated within mitochondria. From there it is released into the bloodstream where it acts on skeletal muscle, fat, liver, and bone.
How is MOTS-c peptide different from GLP-1 or other peptides?+
Most therapeutic peptides (GLP-1 agonists like semaglutide, growth hormone secretagogues, etc.) are encoded in nuclear DNA. MOTS-c is one of a small family of mitochondrial-derived peptides (MDPs), which makes it unique in origin and function — it signals cellular energy status rather than appetite or growth.
References
- Lee C., Zeng J., Drew B.G., et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. View source →
- Reynolds J.C., Lai R.W., Woodhead J.S.T., et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. View source →
- Kim S.J., Mehta H.H., Wan J., et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 2018. View source →
Links open on PubMed or the original journal. Last reviewed dates reflect when our editorial team last verified each citation.